The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Depressive Disorder Market Research Report 2025
Synopsis
Depression includes a variety of mental health problems characterized by the absence of a positive emotion, low mood, and a range of associated cognitive, physical, emotional, and behavioral symptoms. It is a very common condition that affects 1 in every 5 Americans. There are many factors including genes, factors such as stress and brain chemistry that could lead to depression.
The global Depressive Disorder market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The Depressive Disorder market will undergo a period of steady growth from 2015 to 2025, mainly attributed to the growth in atypical antipsychotics and the expected launch of five pipeline.
This report aims to provide a comprehensive presentation of the global market for Depressive Disorder, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Depressive Disorder.
Report Scope
The Depressive Disorder market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Depressive Disorder market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Depressive Disorder companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Alkermes
Allergan
Bristol Myers Squibb
Eli Lilly
Glaxosmithkline
H. Lundbeck
Merck
Pfizer
Teva Pharmaceutical
Takeda Pharmaceutical
Segment by Type
Tricyclic Antidepressants
Selective Serotonin Reuptake Inhibitors
Serotonin-Norepinephrine Reuptake Inhibitors
Monoamine Oxidase Inhibitors
Serotonin Antagonist And Reuptake Inhibitors
Others
Segment by Application
Hospitals
Ambulatory Surgical Centers
Diagnostic Centers
Homecare Settings
Long Term Care Centers
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Depressive Disorder companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Depression includes a variety of mental health problems characterized by the absence of a positive emotion, low mood, and a range of associated cognitive, physical, emotional, and behavioral symptoms. It is a very common condition that affects 1 in every 5 Americans. There are many factors including genes, factors such as stress and brain chemistry that could lead to depression.
The global Depressive Disorder market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The Depressive Disorder market will undergo a period of steady growth from 2015 to 2025, mainly attributed to the growth in atypical antipsychotics and the expected launch of five pipeline.
This report aims to provide a comprehensive presentation of the global market for Depressive Disorder, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Depressive Disorder.
Report Scope
The Depressive Disorder market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Depressive Disorder market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Depressive Disorder companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Alkermes
Allergan
Bristol Myers Squibb
Eli Lilly
Glaxosmithkline
H. Lundbeck
Merck
Pfizer
Teva Pharmaceutical
Takeda Pharmaceutical
Segment by Type
Tricyclic Antidepressants
Selective Serotonin Reuptake Inhibitors
Serotonin-Norepinephrine Reuptake Inhibitors
Monoamine Oxidase Inhibitors
Serotonin Antagonist And Reuptake Inhibitors
Others
Segment by Application
Hospitals
Ambulatory Surgical Centers
Diagnostic Centers
Homecare Settings
Long Term Care Centers
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Depressive Disorder companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Depressive Disorder Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Tricyclic Antidepressants
1.2.3 Selective Serotonin Reuptake Inhibitors
1.2.4 Serotonin-Norepinephrine Reuptake Inhibitors
1.2.5 Monoamine Oxidase Inhibitors
1.2.6 Serotonin Antagonist And Reuptake Inhibitors
1.2.7 Others
1.3 Market by Application
1.3.1 Global Depressive Disorder Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Hospitals
1.3.3 Ambulatory Surgical Centers
1.3.4 Diagnostic Centers
1.3.5 Homecare Settings
1.3.6 Long Term Care Centers
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Depressive Disorder Market Perspective (2019-2030)
2.2 Depressive Disorder Growth Trends by Region
2.2.1 Global Depressive Disorder Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Depressive Disorder Historic Market Size by Region (2019-2024)
2.2.3 Depressive Disorder Forecasted Market Size by Region (2025-2030)
2.3 Depressive Disorder Market Dynamics
2.3.1 Depressive Disorder Industry Trends
2.3.2 Depressive Disorder Market Drivers
2.3.3 Depressive Disorder Market Challenges
2.3.4 Depressive Disorder Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Depressive Disorder Players by Revenue
3.1.1 Global Top Depressive Disorder Players by Revenue (2019-2024)
3.1.2 Global Depressive Disorder Revenue Market Share by Players (2019-2024)
3.2 Global Depressive Disorder Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Depressive Disorder Revenue
3.4 Global Depressive Disorder Market Concentration Ratio
3.4.1 Global Depressive Disorder Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Depressive Disorder Revenue in 2023
3.5 Depressive Disorder Key Players Head office and Area Served
3.6 Key Players Depressive Disorder Product Solution and Service
3.7 Date of Enter into Depressive Disorder Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Depressive Disorder Breakdown Data by Type
4.1 Global Depressive Disorder Historic Market Size by Type (2019-2024)
4.2 Global Depressive Disorder Forecasted Market Size by Type (2025-2030)
5 Depressive Disorder Breakdown Data by Application
5.1 Global Depressive Disorder Historic Market Size by Application (2019-2024)
5.2 Global Depressive Disorder Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Depressive Disorder Market Size (2019-2030)
6.2 North America Depressive Disorder Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Depressive Disorder Market Size by Country (2019-2024)
6.4 North America Depressive Disorder Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Depressive Disorder Market Size (2019-2030)
7.2 Europe Depressive Disorder Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Depressive Disorder Market Size by Country (2019-2024)
7.4 Europe Depressive Disorder Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Depressive Disorder Market Size (2019-2030)
8.2 Asia-Pacific Depressive Disorder Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Depressive Disorder Market Size by Region (2019-2024)
8.4 Asia-Pacific Depressive Disorder Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Depressive Disorder Market Size (2019-2030)
9.2 Latin America Depressive Disorder Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Depressive Disorder Market Size by Country (2019-2024)
9.4 Latin America Depressive Disorder Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Depressive Disorder Market Size (2019-2030)
10.2 Middle East & Africa Depressive Disorder Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Depressive Disorder Market Size by Country (2019-2024)
10.4 Middle East & Africa Depressive Disorder Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Alkermes
11.1.1 Alkermes Company Detail
11.1.2 Alkermes Business Overview
11.1.3 Alkermes Depressive Disorder Introduction
11.1.4 Alkermes Revenue in Depressive Disorder Business (2019-2024)
11.1.5 Alkermes Recent Development
11.2 Allergan
11.2.1 Allergan Company Detail
11.2.2 Allergan Business Overview
11.2.3 Allergan Depressive Disorder Introduction
11.2.4 Allergan Revenue in Depressive Disorder Business (2019-2024)
11.2.5 Allergan Recent Development
11.3 Bristol Myers Squibb
11.3.1 Bristol Myers Squibb Company Detail
11.3.2 Bristol Myers Squibb Business Overview
11.3.3 Bristol Myers Squibb Depressive Disorder Introduction
11.3.4 Bristol Myers Squibb Revenue in Depressive Disorder Business (2019-2024)
11.3.5 Bristol Myers Squibb Recent Development
11.4 Eli Lilly
11.4.1 Eli Lilly Company Detail
11.4.2 Eli Lilly Business Overview
11.4.3 Eli Lilly Depressive Disorder Introduction
11.4.4 Eli Lilly Revenue in Depressive Disorder Business (2019-2024)
11.4.5 Eli Lilly Recent Development
11.5 Glaxosmithkline
11.5.1 Glaxosmithkline Company Detail
11.5.2 Glaxosmithkline Business Overview
11.5.3 Glaxosmithkline Depressive Disorder Introduction
11.5.4 Glaxosmithkline Revenue in Depressive Disorder Business (2019-2024)
11.5.5 Glaxosmithkline Recent Development
11.6 H. Lundbeck
11.6.1 H. Lundbeck Company Detail
11.6.2 H. Lundbeck Business Overview
11.6.3 H. Lundbeck Depressive Disorder Introduction
11.6.4 H. Lundbeck Revenue in Depressive Disorder Business (2019-2024)
11.6.5 H. Lundbeck Recent Development
11.7 Merck
11.7.1 Merck Company Detail
11.7.2 Merck Business Overview
11.7.3 Merck Depressive Disorder Introduction
11.7.4 Merck Revenue in Depressive Disorder Business (2019-2024)
11.7.5 Merck Recent Development
11.8 Pfizer
11.8.1 Pfizer Company Detail
11.8.2 Pfizer Business Overview
11.8.3 Pfizer Depressive Disorder Introduction
11.8.4 Pfizer Revenue in Depressive Disorder Business (2019-2024)
11.8.5 Pfizer Recent Development
11.9 Teva Pharmaceutical
11.9.1 Teva Pharmaceutical Company Detail
11.9.2 Teva Pharmaceutical Business Overview
11.9.3 Teva Pharmaceutical Depressive Disorder Introduction
11.9.4 Teva Pharmaceutical Revenue in Depressive Disorder Business (2019-2024)
11.9.5 Teva Pharmaceutical Recent Development
11.10 Takeda Pharmaceutical
11.10.1 Takeda Pharmaceutical Company Detail
11.10.2 Takeda Pharmaceutical Business Overview
11.10.3 Takeda Pharmaceutical Depressive Disorder Introduction
11.10.4 Takeda Pharmaceutical Revenue in Depressive Disorder Business (2019-2024)
11.10.5 Takeda Pharmaceutical Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
